Public Employees Retirement System of Ohio Acquires 19,775 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)

Public Employees Retirement System of Ohio increased its position in Fate Therapeutics, Inc. (NASDAQ:FATE) by 14.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 154,178 shares of the biopharmaceutical company’s stock after buying an additional 19,775 shares during the quarter. Public Employees Retirement System of Ohio owned 0.16% of Fate Therapeutics worth $327,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently made changes to their positions in the company. American Century Companies Inc. increased its stake in shares of Fate Therapeutics by 74.7% in the third quarter. American Century Companies Inc. now owns 37,062 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 15,848 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Fate Therapeutics by 2.3% in the third quarter. Jacobs Levy Equity Management Inc. now owns 2,389,123 shares of the biopharmaceutical company’s stock worth $5,065,000 after buying an additional 54,005 shares during the period. GSA Capital Partners LLP increased its stake in shares of Fate Therapeutics by 30.4% in the third quarter. GSA Capital Partners LLP now owns 253,429 shares of the biopharmaceutical company’s stock worth $537,000 after buying an additional 59,019 shares during the period. Laurion Capital Management LP increased its position in Fate Therapeutics by 128.6% during the 3rd quarter. Laurion Capital Management LP now owns 35,173 shares of the biopharmaceutical company’s stock valued at $75,000 after purchasing an additional 19,787 shares during the period. Finally, Ameriprise Financial Inc. increased its position in Fate Therapeutics by 11.0% during the 3rd quarter. Ameriprise Financial Inc. now owns 275,492 shares of the biopharmaceutical company’s stock valued at $584,000 after purchasing an additional 27,394 shares during the period. 97.54% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on FATE. Oppenheimer reissued a “market perform” rating on shares of Fate Therapeutics in a research report on Tuesday, February 27th. Morgan Stanley boosted their price objective on shares of Fate Therapeutics from $3.00 to $7.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 27th. Wedbush boosted their price objective on shares of Fate Therapeutics from $3.00 to $7.00 and gave the company a “neutral” rating in a research report on Tuesday, February 27th. Barclays boosted their price objective on shares of Fate Therapeutics from $6.00 to $10.00 and gave the company an “overweight” rating in a research report on Tuesday, February 27th. Finally, HC Wainwright reissued a “neutral” rating and set a $7.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, March 19th. Nine investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and an average target price of $6.80.

Insider Buying and Selling

In related news, CFO Edward J. Dulac III sold 7,028 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $4.37, for a total value of $30,712.36. Following the completion of the sale, the chief financial officer now directly owns 105,775 shares of the company’s stock, valued at approximately $462,236.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Bahram Valamehr sold 11,271 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $4.38, for a total transaction of $49,366.98. Following the completion of the transaction, the insider now directly owns 158,069 shares in the company, valued at approximately $692,342.22. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Edward J. Dulac III sold 7,028 shares of the stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $4.37, for a total value of $30,712.36. Following the transaction, the chief financial officer now owns 105,775 shares of the company’s stock, valued at $462,236.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 45,413 shares of company stock valued at $199,732. 5.04% of the stock is owned by corporate insiders.

Fate Therapeutics Trading Up 7.0 %

Shares of FATE stock opened at $7.34 on Thursday. The company’s fifty day moving average price is $6.64 and its 200-day moving average price is $4.02. The stock has a market cap of $728.42 million, a PE ratio of -4.48 and a beta of 1.67. Fate Therapeutics, Inc. has a 12 month low of $1.63 and a 12 month high of $8.83.

Fate Therapeutics (NASDAQ:FATE) last released its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.12. The company had revenue of $1.68 million during the quarter, compared to analyst estimates of $0.85 million. Fate Therapeutics had a negative net margin of 253.30% and a negative return on equity of 38.17%. During the same period in the prior year, the firm posted ($0.58) EPS. On average, sell-side analysts forecast that Fate Therapeutics, Inc. will post -1.89 earnings per share for the current fiscal year.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.